Release Notes: Version 20191108
About this maintenance release
This release includes the Canadian Clinical Drug Data Set files (version 20191108).
The Editorial Guidelines and the Technical Specification have not been revised with this release.
The Canadian Clinical Drug Data Set is available for browsing and download via the Infoway Terminology Gateway.
Supporting general information can be found on Infoway Canadian Clinical Drug Data Set InfoCentral page.
General Notes
The following files will be available as full release files within this version:
- Manufactured Product,
- Non-proprietary Therapeutic Product,
- Therapeutic Moiety,
- Manufactured Product, Non-proprietary Therapeutic Product, Therapeutic Product Relationship,
- Special Groupings,
- Coded Attribute, and
- Device Non-proprietary Therapeutic Product.
The 'Full" release contains one entry for every concept that has ever been released and new content added for that release. New content added for a specific release may at times include “Inactive” content.
NOTE: The “Delta" release which is intended to contain only those concepts that have been added or changed since the previous release will be considered for a future enhancement at a later date.
This release continues to add additional content from the DPD and includes all of the top 250 moieties and approximately 99% of the DPD content in scope for CCDD.
The table below provides the number of concepts within each CCDD file for this release.
November 2019 CCDD Files | Number of Concepts | Types of Changes in this release |
|---|---|---|
| Therapeutic Moiety Full Release | 1460 | 5 additions
|
| Non-proprietary Therapeutic Product Full Release | 4320 | 22 additions 2 formal name changes with no change in code (see technical correction details below) 6 status changes
1 status date change with no change of status |
| Manufactured Product Full Release | 11685 | 67 additions Formal name changes made:
33 status changes from active to inactive 3 status changes from inactive to active 1 status date changes (no change of status) 1 Health Canada product name with no change to mp formal name or code (see below) |
Manufactured Product, Non-proprietary Therapeutic Product, Therapeutic Moiety Relationship | 11678 | Includes concept additions and changes as above Deprecated concepts have been excluded. |
| Device Non-proprietary Therapeutic Product | 3 | no change |
| Special Groupings | 1848 | 8 additional concepts added Includes concept changes as above |
| Coded Attributes | 7 | no change |
NTP Changes
The following NTP changes occurred:
| 9014165 | dinoprostone 0.3 mg per hour vaginal delivery system | Active | this concept is new in November and replaces the deprecated concept of 9003108 | NA | NA | NA |
| 9003108 | dinoprostone 10 mg per insert vaginal delivery system | Deprec | correction required for dose strength | 9003108 | dinoprostone 10 mg per insert vaginal delivery system | Active |
ntp_code November Release | ntp_formal_name November Release | November Status | Comments | ntp_code October Release | ntp_formal_name October Release | October Status |
|---|
Please find the following 2 technical correction type of changes with no change in code as follows:
| 9003170 | hypromellose 3 mg per g ophthalmic drops | Change in strength | 9003170 | hypromellose 3 mg per mL ophthalmic drops |
| 9008749 | desogestrel 100 mcg and estradiol 25 mcg oral tablet with desogestrel 125 mcg and estradiol 25 mcg oral tablet with desogestrel 150 mcg and ethinyl estradiol 25 mcg oral tablet with lactose oral tablet | Removal of extraneous space | 9008749 | desogestrel 100 mcg and estradiol 25 mcg oral tablet with desogestrel 125 mcg and estradiol 25 mcg oral tablet with desogestrel 150 mcg and ethinyl estradiol 25 mcg oral tablet with lactose oral tablet |
ntp_code November Release | ntp_formal_name November Release | Type of Change | ntp_code October Release | ntp_formal_name October Release |
|---|
MP Changes
In addition to the changes as a result NTP corrections, please find the following MP formal name changes:
| 00653217 | TEVA-ECTOSONE SCALP LOTION (betamethasone (betamethasone valerate) 0.1 % lotion) TEVA CANADA LIMITED | Addition of DPD descriptor to product name (to differentiate it from an otherwise identical product) | 00653217 | TEVA-ECTOSONE (betamethasone (betamethasone valerate) 0.1 % lotion) TEVA CANADA LIMITED |
| 02316838 | ACTONEL (risedronate sodium (risedronate sodium hemipentahydrate) 150 mg oral tablet) ALLERGAN INC | spelling correction | 02316838 | ACTONEL (risedronate sodium (risedronate sodium hemi-pentahydrate) 150 mg oral tablet) ALLERGAN INC |
| 02239146 | ACTONEL (risedronate sodium (risedronate sodium hemipentahydrate) 30 mg oral tablet) ALLERGAN PHARMA CO. | spelling correction | 02239146 | ACTONEL (risedronate sodium (risedronate sodium hemi-pentahydrate) 30 mg oral tablet) ALLERGAN PHARMA CO. |
| 02246896 | ACTONEL (risedronate sodium (risedronate sodium hemipentahydrate) 35 mg oral tablet) ALLERGAN INC | spelling correction | 02246896 | ACTONEL (risedronate sodium (risedronate sodium hemi-pentahydrate) 35 mg oral tablet) ALLERGAN INC |
| 02242518 | ACTONEL (risedronate sodium (risedronate sodium hemipentahydrate) 5 mg oral tablet) ALLERGAN PHARMA CO. | spelling correction | 02242518 | ACTONEL (risedronate sodium (risedronate sodium hemi-pentahydrate) 5 mg oral tablet) ALLERGAN PHARMA CO. |
| 02370417 | ACTONEL DR (risedronate sodium (risedronate sodium hemipentahydrate) 35 mg gastro-resistant tablet) ALLERGAN INC | spelling correction | 02370417 | ACTONEL DR (risedronate sodium (risedronate sodium hemi-pentahydrate) 35 mg gastro-resistant tablet) ALLERGAN INC |
| 02377721 | APO-RISEDRONATE (risedronate sodium (risedronate sodium hemipentahydrate) 150 mg oral tablet) APOTEX INC | spelling correction | 02377721 | APO-RISEDRONATE (risedronate sodium (risedronate sodium hemi-pentahydrate) 150 mg oral tablet) APOTEX INC |
| 02353687 | APO-RISEDRONATE (risedronate sodium (risedronate sodium hemipentahydrate) 35 mg oral tablet) APOTEX INC | spelling correction | 02353687 | APO-RISEDRONATE (risedronate sodium (risedronate sodium hemi-pentahydrate) 35 mg oral tablet) APOTEX INC |
| 02442760 | AURO-RISEDRONATE (risedronate sodium (risedronate sodium hemipentahydrate) 150 mg oral tablet) AURO PHARMA INC | spelling correction | 02442760 | AURO-RISEDRONATE (risedronate sodium (risedronate sodium hemi-pentahydrate) 150 mg oral tablet) AURO PHARMA INC |
| 02406306 | AURO-RISEDRONATE (risedronate sodium (risedronate sodium hemipentahydrate) 35 mg oral tablet) AURO PHARMA INC | spelling correction | 02406306 | AURO-RISEDRONATE (risedronate sodium (risedronate sodium hemi-pentahydrate) 35 mg oral tablet) AURO PHARMA INC |
| 02309831 | DOM-RISEDRONATE (risedronate sodium (risedronate sodium hemipentahydrate) 35 mg oral tablet) DOMINION PHARMACAL | spelling correction | 02309831 | DOM-RISEDRONATE (risedronate sodium (risedronate sodium hemi-pentahydrate) 35 mg oral tablet) DOMINION PHARMACAL |
| 02368552 | JAMP-RISEDRONATE (risedronate sodium (risedronate sodium hemipentahydrate) 35 mg oral tablet) JAMP PHARMA CORPORATION | spelling correction | 02368552 | JAMP-RISEDRONATE (risedronate sodium (risedronate sodium hemi-pentahydrate) 35 mg oral tablet) JAMP PHARMA CORPORATION |
| 02397773 | MYLAN-RISEDRONATE (risedronate sodium (risedronate sodium hemipentahydrate) 150 mg oral tablet) MYLAN PHARMACEUTICALS ULC | spelling correction | 02397773 | MYLAN-RISEDRONATE (risedronate sodium (risedronate sodium hemi-pentahydrate) 150 mg oral tablet) MYLAN PHARMACEUTICALS ULC |
| 02357984 | MYLAN-RISEDRONATE (risedronate sodium (risedronate sodium hemipentahydrate) 35 mg oral tablet) MYLAN PHARMACEUTICALS ULC | spelling correction | 02357984 | MYLAN-RISEDRONATE (risedronate sodium (risedronate sodium hemi-pentahydrate) 35 mg oral tablet) MYLAN PHARMACEUTICALS ULC |
| 02424177 | PMS-RISEDRONATE (risedronate sodium (risedronate sodium hemipentahydrate) 150 mg oral tablet) PHARMASCIENCE INC | spelling correction | 02424177 | PMS-RISEDRONATE (risedronate sodium (risedronate sodium hemi-pentahydrate) 150 mg oral tablet) PHARMASCIENCE INC |
| 02302209 | PMS-RISEDRONATE (risedronate sodium (risedronate sodium hemipentahydrate) 35 mg oral tablet) PHARMASCIENCE INC | spelling correction | 02302209 | PMS-RISEDRONATE (risedronate sodium (risedronate sodium hemi-pentahydrate) 35 mg oral tablet) PHARMASCIENCE INC |
| 02347474 | RISEDRONATE (risedronate sodium (risedronate sodium hemipentahydrate) 35 mg oral tablet) PRO DOC LIMITEE | spelling correction | 02347474 | RISEDRONATE (risedronate sodium (risedronate sodium hemi-pentahydrate) 35 mg oral tablet) PRO DOC LIMITEE |
| 02352141 | RISEDRONATE (risedronate sodium (risedronate sodium hemipentahydrate) 35 mg oral tablet) SIVEM PHARMACEUTICALS ULC | spelling correction | 02352141 | RISEDRONATE (risedronate sodium (risedronate sodium hemi-pentahydrate) 35 mg oral tablet) SIVEM PHARMACEUTICALS ULC |
| 02341077 | RIVA-RISEDRONATE (risedronate sodium (risedronate sodium hemipentahydrate) 35 mg oral tablet) LABORATOIRE RIVA INC | spelling correction | 02341077 | RIVA-RISEDRONATE (risedronate sodium (risedronate sodium hemi-pentahydrate) 35 mg oral tablet) LABORATOIRE RIVA INC |
| 02327295 | SANDOZ RISEDRONATE (risedronate sodium (risedronate sodium hemipentahydrate) 35 mg oral tablet) SANDOZ CANADA INCORPORATED | spelling correction | 02327295 | SANDOZ RISEDRONATE (risedronate sodium (risedronate sodium hemi-pentahydrate) 35 mg oral tablet) SANDOZ CANADA INCORPORATED |
mp_code November Release | mp_formal_name November Release | Type of Change | mp_code October Release | mp_formal_name October Release |
|---|
In addition, there is one concept with a change in Health_Canada-product_name with no change to MP formal name
| 00745626 | HUMATROPE (somatropin 5 mg per vial powder for solution for injection with diluent solution) ELI LILLY CANADA INC | Health_Canada-product_name change | HUMATROPE | HUMATROPE INJ 1MG/ML |
mp_code (no change) | mp_formal_name (no change) | Type of Change | Health_Canada_product_name November Release | Health_Canada_product_name October Release |
|---|
Questions, Concerns, Changes
Questions and concerns and suggestions for future consideration are welcomed and should be sent by e-mail at [email protected]